Company research
Aligos Therapeutics, Inc.
CIK 1799448Updated Sep 27, 2026
SecurityALGS · NASDAQ · equity
ALGS price & chart
Loading TradingView…
NASDAQ:ALGS on TradingView ↗About the company
Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biopharmaceutical company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics for diseases with high unmet medical need such as chronic hepatitis B virus infection (CHB), metabolic dysfunction-associated steatohepatitis (MASH), and coronaviruses.
In the news
Aligos Therapeutics Presents Positive Data at the EASL Congress 2026 ↗
Recent filings
Entry into a Material Definitive Agreement
Items 1.01
S-8 filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
4 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 88,533,000Source | 70,094,000Source | 151,527,000Source | 146,693,000Source |
| Property, Plant and Equipment, NetUSD | 1,867,000Source | 2,362,000Source | 3,259,000Source | 4,816,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 18,303,000Source | 36,997,000Source | 135,704,000Source | 81,347,000Source |
| Assets, CurrentUSD | 82,862,000Source | 62,141,000Source | 141,084,000Source | 133,545,000Source |
| Operating Lease, Right-of-Use AssetUSD | 3,089,000Source | 4,964,000Source | 6,559,000Source | 7,698,000Source |
| Other Assets, NoncurrentUSD | 715,000Source | 627,000Source | 625,000Source | 634,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 34,988,000Source | 99,067,000Source | 59,447,000Source | 42,793,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | — | — | — |
| Common Stock, Value, IssuedUSD | 9,000Source | 8,000Source | 7,000Source | 4,000Source |
| Retained Earnings (Accumulated Deficit)USD | -642,201,000Source | -618,008,000Source | -486,797,000Source | -399,118,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 468,000Source | 451,000Source | 545,000Source | 401,000Source |
| Stockholders' Equity Attributable to ParentUSD | 53,545,000Source | -28,973,000Source | 92,080,000Source | 103,900,000Source |
| Additional Paid in Capital, Common StockUSD | 695,269,000Source | 588,576,000Source | 578,325,000Source | 502,613,000Source |
| Liabilities and EquityUSD | 88,533,000Source | 70,094,000Source | 151,527,000Source | 146,693,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 21,233,000Source | 21,737,000Source | 23,906,000Source | 33,129,000Source |
| Operating Lease, Liability, CurrentUSD | 3,580,000Source | 3,422,000Source | 3,229,000Source | 3,035,000Source |
| Accounts Payable, CurrentUSD | 3,982,000Source | 2,571,000Source | 2,517,000Source | 4,737,000Source |
| Operating Lease, Liability, NoncurrentUSD | 1,525,000Source | 4,795,000Source | 7,668,000Source | 9,201,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 13,526,000Source | 15,557,000Source | 16,842,000Source | 16,039,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 77,800,000Source | 56,900,000Source | 135,700,000Source | 125,800,000Source |
| Deferred Revenue, CurrentUSD | 0Source | 151,000Source | — | — |
| Short-term InvestmentsUSD | 59,541,000Source | 19,942,000Source | — | 44,480,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 5,044,000Source | 8,452,000Source | 12,652,000Source | 14,693,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | 1,411,000Source | 54,000Source | -2,219,000Source | 1,722,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | 0Source | 0Source | 0Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -82,503,000Source | -80,743,000Source | -78,997,000Source | -79,389,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -37,826,000Source | -18,279,000Source | 44,981,000Source | -26,293,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | 130,000Source | 19,000Source | 943,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 101,635,000Source | 355,000Source | 88,328,000Source | 164,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 18,413,000Source | 37,107,000Source | 135,774,000Source | 81,462,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Income Taxes Paid, NetUSD | 315,000Source | — | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 5,044,000Source | 8,452,000Source | — | 14,693,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 77,800,000Source | 56,900,000Source | 135,700,000Source | 125,800,000Source |
| DepreciationUSD | 930,000Source | 1,027,000Source | 1,559,000Source | 2,306,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 200,000Source | 3,400Source | 45,700Source | 42,000Source |
| Gain (Loss) on Disposition of AssetsUSD | — | — | -17,000Source | — |
| Gain (Loss) on Sale of InvestmentsUSD | — | — | — | -57,000Source |
| General and Administrative ExpenseUSD | 20,718,000Source | 22,830,000Source | 30,616,000Source | 26,410,000Source |
| Income Tax Expense (Benefit)USD | 314,000Source | 331,000Source | 795,000Source | 106,000Source |
| Net Income (Loss) Attributable to ParentUSD | -24,193,000Source | -131,211,000Source | -87,679,000Source | -96,046,000Source |
| Operating ExpensesUSD | 90,171,000Source | 93,099,000Source | 103,656,000Source | 111,487,000Source |
| Operating Lease, Impairment LossUSD | — | — | 724,000Source | — |
| Other Operating Income (Expense), NetUSD | 3,922,000Source | 4,406,000Source | 1,243,000Source | 1,640,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 2,186,000Source | 3,611,000Source | 6,191,000Source | 0Source |
| Operating Income (Loss)USD | -87,985,000Source | -89,154,000Source | -88,127,000Source | -97,580,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -23,879,000Source | -130,880,000Source | -86,884,000Source | -95,940,000Source |
| Income Tax Expense (Benefit)USD | 314,000Source | 331,000Source | 795,000Source | 106,000Source |
| Net Income (Loss) Attributable to ParentUSD | -24,193,000Source | -131,211,000Source | -87,679,000Source | -96,046,000Source |
| Earnings Per Share, BasicUSD per share | -2.45Source | -20.94Source | -1.36Source | — |
| Earnings Per Share, DilutedUSD per share | -2.45Source | -20.94Source | -1.36Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 9,884,955Source | 6,264,612Source | 64,260,588Source | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 9,884,955Source | 6,264,612Source | 64,260,588Source | — |
| Additional Financial Items | ||||
| Current Income Tax Expense (Benefit)USD | 314,000Source | 331,000Source | 795,000Source | 106,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 200,000Source | 3,400Source | 45,700Source | 42,000Source |
| General and Administrative ExpenseUSD | 20,718,000Source | 22,830,000Source | 30,616,000Source | 26,410,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -20,765,000Source | — | — | — |
| Interest Income (Expense), NetUSD | 2,200,000Source | 1,700,000Source | 4,300,000Source | — |
| Operating ExpensesUSD | 90,171,000Source | 93,099,000Source | 103,656,000Source | 111,487,000Source |
| Other Operating Income (Expense), NetUSD | 3,922,000Source | 4,406,000Source | 1,243,000Source | 1,640,000Source |
| Research and Development ExpenseUSD | 69,453,000Source | 70,269,000Source | 73,040,000Source | 85,077,000Source |
Filing attachments
d107028dex991.htm · 8-K · 2026-04-14
EX-99.1 2 d107028dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track Designation Received FDA Fast Track Designation for pevifoscorvir sodium for the treatment of chronic hepatitis B virus infection HBeAg- cohort sample size increased to optimize powering; futility criteria not met ───────────…
Read attachment ↗d901857dex41.htm · 8-K · 2025-02-12
EX-4.1 2 d901857dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES OR IN ANY OTHER JURISDICTION. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE OFFERED, SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR …
Read attachment ↗d901857dex42.htm · 8-K · 2025-02-12
EX-4.2 3 d901857dex42.htm EX-4.2 EX-4.2 Exhibit 4.2 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES, OR IN ANY OTHER JURISDICTION. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE OFFERED, SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR…
Read attachment ↗d901857dex991.htm · 8-K · 2025-02-12
EX-99.1 8 d901857dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Aligos Therapeutics Announces $105 Million Private Placement Financing Proceeds expected to fund the start of the ALG-000184 Phase 2 clinical study Funding expected to extend cash runway into the second half of 2026 SOUTH SAN FRANCISCO, Calif., February 12, 2025 (GLOBE NEWSWIRE) - Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biotechnology company focused on improving patient outcomes through best…
Read attachment ↗